NCT06037148View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

March 6, 2024

Study Completion Date

March 6, 2024

Conditions

Birch Pollen Allergy

Interventions

BIOLOGICAL

DM-101PX

subcutaneous injection of DM-101PX

BIOLOGICAL

Placebo to Match DM-101PX

Placebo to match DM-101PX administered subcutaneously

Trial Locations (1)

ON L4W 1A4

Cliantha Research, Mississauga

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Desentum Oy

INDUSTRY